Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 1, 2006, Pages 59-64

  Niblock, Paddy ^a   Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen deprivation therapy; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

DISEASES; PATIENT MONITORING; RADIOTHERAPY; TUMORS;

ANDROGEN DEPRIVATION THERAPY; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN;

ANTIGENS;

ANTIANDROGEN; ESTROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CHI SQUARE TEST; CONTROLLED STUDY; CORRELATION COEFFICIENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; RANK SUM TEST; SURVIVAL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 33645997697     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.09.048     Document Type: Article

References (32)

1. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
2. Zagars G.K., Pollack A., and von Eschenbach A.C. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58 (2001) 233-239
3. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). A phase III randomised trial. Lancet 360 (2002) 103-106
4. Kataja V.V. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 14 (2003) 1010-1011
5. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 292 (2004) 821-827
6. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
7. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy. Consensus development. Can J Urol 8 (2001) 1314-1322
8. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
9. Taylor J.M., Griffith K.A., and Sandler H.M. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 1212-1219
10. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
11. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation, and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
12. Hanlon A.L., Hanks G.E., and American Society for Therapeutic Radiology and Oncology. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 46 (2000) 559-566
13. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 61 (2005) 1291-1298
14. Lukka H., Hayter C., Warde P., et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer [Abstract]. Int J Radiat Oncol Biol Phys 57 Suppl. 1 (2003) S126
15. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol-a protocol for reversible medical castration. Urology 47 (1996) 882-884
16. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
17. Laverdiere J., Nabid A., De Bedoya L.D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (2004) 1137-1140
18. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
19. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 15-23
20. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96. 01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
21. Nilsson S., Norlen B.J., and Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43 (2004) 316-381
22. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
23. Sumi M., Ikeda H., Tokuuye K., et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Int J Radiat Oncol Biol Phys 48 (2000) 519-528
24. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy. An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32 (1995) 287-292
25. Ludgate C.M., Bishop D.C., Pai H., et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer. The importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 62 (2005) 1309-1315
26. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213-219
27. Ruckle H.C., and Oesterling J.E. Prostate-specific antigen and androgen deprivation therapy. World J Urol 11 (1993) 227-232
28. Pollack A., Hanlon A.L., Movsas B., et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 19-23
29. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
30. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64 (2004) 6595-6602
31. Gleave M.E., Miyake H., Zellweger T., et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58 (2001) 39-49
32. Cesinaro A.M., Migaldi M., Ferrari G., et al. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy. Oncol Res 12 (2000) 43-49